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SUMMARY

Targeting defects in metabolism is an underutilized
strategy for the treatment of cancer. Arginine auxotrophy resulting from the silencing of argininosuccinate synthetase 1 (ASS1) is a common metabolic
alteration reported in a broad range of aggressive
cancers. To assess the metabolic effects that
arise from acute and chronic arginine starvation in
ASS1-deficient cell lines, we performed metabolite
profiling. We found that pharmacologically induced
arginine depletion causes increased serine biosynthesis, glutamine anaplerosis, oxidative phosphorylation, and decreased aerobic glycolysis, effectively
inhibiting the Warburg effect. The reduction of
glycolysis in cells otherwise dependent on aerobic
glycolysis is correlated with reduced PKM2 expression and phosphorylation and upregulation of
PHGDH. Concurrent arginine deprivation and glutaminase inhibition was found to be synthetic lethal
across a spectrum of ASS1-deficient tumor cell lines
and is sufficient to cause in vivo tumor regression
in mice. These results identify two synthetic lethal
therapeutic strategies exploiting metabolic vulnerabilities of ASS1-negative cancers.
INTRODUCTION
Metabolic reprogramming is a well established hallmark of
cancer that remains to be fully exploited therapeutically

(DeBerardinis et al., 2008; Hanahan and Weinberg, 2011). Common metabolic alterations in malignancies include the loss of
argininosuccinate synthetase 1 (ASS1) expression and the
energetic phenotype known as the Warburg effect (Dillon et al.,
2004; Warburg, 1956). The Warburg effect refers to the preferential generation of ATP through aerobic glycolysis as opposed
to mitochondrial oxidative phosphorylation (OxPhos) despite
adequate oxygen levels (Warburg, 1956). The Warburg effect
results in increased generation of glucose-derived biomass
required for unrestrained cellular proliferation and tumor growth
(DeBerardinis et al., 2008; Icard and Lincet, 2012; Lunt and Vander Heiden, 2011). Recent studies have also shown that the Warburg effect is important in providing rapidly proliferating cells
with an electron acceptor in the form of pyruvate, necessary in
the oxidative biosynthesis of aspartate (Birsoy et al., 2015).
Aspartate is utilized for the biosynthesis of proteins, purines,
and pyrimidines, and insufficient aspartate levels inhibit proliferation (Birsoy et al., 2015; Sullivan et al., 2015).
Meeting the specific energy needs of cancer cells often requires differential regulation of one or more metabolic enzymes.
Pyruvate kinase muscle isozymes (PKMs), especially the embryonic splice isoform PKM2, are critical to rapidly dividing cells and
are expressed exclusively in cells undergoing high levels of proliferation, such as embryonic and tumor cells (Chaneton and Gottlieb, 2012). Although the alternatively spliced isoform PKM1 is
expressed in healthy cells, tumor formation coincides with dramatic increases in PKM2 expression (Chen et al., 2010; Christofk
ska et al., 1997; Hitosugi et al., 2009; Macinet al., 2008; Gumin
tyre and Rathmell, 2011). Further highlighting the tumorigenic
consequences of altered PKM isoform expression, PKM2
expression has been shown to be sufficient, but not necessary,
for induction of the Warburg effect, whereas overexpression of
PKM1 results in inhibition of growth and proliferation of tumor
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€ning et al., 2011; Icard and Lincet,
cells (Chen et al., 2010; Gru
2012; Marı́n-Hernández et al., 2009). PKM2 has been shown to
be degraded through acetylation and subsequent chaperonemediated autophagy under certain cellular contexts, prompting
one approach to therapeutically target cancer metabolism by
manipulation of PKM2 activity and protein levels (Cheong et al.,
2012; Lv et al., 2011; Macintyre and Rathmell, 2011).
Phosphorylation of PKM2 decreases enzymatic activity, resulting in a lower rate of conversion of phosphoenolpyruvate
(PEP) to pyruvate and altered glycolytic kinetics (Christofk
et al., 2008; Hitosugi et al., 2009). A decreased pyruvate level reduces the flux of glycolytic metabolites into the tricarboxylic acid
(TCA) cycle. However, the generation of lactate or acetyl-coenzyme A (CoA) from pyruvate ultimately depends on the regulation
of cellular lactate dehydrogenases (LDH) and pyruvate dehydrogenases (PDH), respectively (Fan et al., 2011; Rardin et al., 2009).
The inhibition of the terminal step of glycolysis by PKM2 phosphorylation leads to the buildup of glycolytic intermediates that
are shunted into the pentose phosphate pathway (PPP) and
other biosynthetic pathways to facilitate the synthesis of nucleic
acids, amino acids, lipids, and other cellular building blocks
€ning et al., 2011; Gumin
needed for cell growth and division (Gru
ska et al., 1997; Hitosugi et al., 2009; Icard and Lincet, 2012;
Locasale et al., 2011; Macintyre and Rathmell, 2011). The amino
acid serine acts as a natural allosteric activator of PKM2 in a regulatory feedback loop (Chaneton et al., 2012; Kung et al., 2012).
PKM2 functions as a serine biosynthetic rheostat by increasing
the rate of serine biosynthesis when enzymatically inactive until
serine levels reach a minimal threshold and allosterically activate
the enzymatic activity of PKM2 (Ye et al., 2012). This increase in
PKM2 activity leads to decreased concentrations of glycolytic
metabolites and subsequent decreases in the flux of glucosederived carbon into serine biosynthesis. Therefore, PKM2 plays
an important role in maintaining serine levels sufficient for cellular
growth and proliferation (Chaneton et al., 2012; Kung et al., 2012;
Locasale et al., 2011; Ye et al., 2012).
Another common metabolic alteration observed in many
cancers is the silencing of the ASS1 gene that encodes the ratelimiting enzyme in the urea cycle, the metabolic pathway responsible for the clearance of nitrogenous waste and the biosynthesis
of arginine (Delage et al., 2010). Because ASS1 catalyzes the formation of argininosuccinate from citrulline and aspartate, recent
studies have found that the loss of ASS1 protein expression results in increased cellular abundance of aspartate and subsequent aspartate utilization in nucleotide and protein biosynthesis
(Rabinovich et al., 2015). Additional studies have shown that
loss of ASS1 expression is a prognostic biomarker of reduced
metastasis-free survival in a variety of cancers (Allen et al., 2014;
Changou et al., 2014; Kobayashi et al., 2010; Mok et al., 2007;
Nicholson et al., 2009; Szlosarek et al., 2006). Loss of ASS1
expression leads to dependence upon extracellular arginine for

continued cell growth, proliferation, and survival, known as arginine auxotrophy. Exploiting this auxotrophy through arginine starvation induces autophagy to maintain cell survival (Bean et al.,
2016; Kim et al., 2009; Nicholson et al., 2009; Syed et al., 2013).
Preliminary studies, including clinical trials, have targeted
ASS1 loss with the pegylated form arginine deiminase (ADIPEG20), an enzyme that degrades arginine to citrulline, causing
significant tumor growth inhibition. These studies have investigated certain types of sarcoma, melanoma, hepatocellular carcinoma, prostate cancer, leukemia, lymphoma, and pancreatic
cancer (Bean et al., 2016; Delage et al., 2010, 2012; MirakiMoud et al., 2015). Prolonged treatment with ADI-PEG20 has
been shown to induce re-expression of ASS1 and subsequent
resistance to arginine starvation (Feun et al., 2012; Shen et al.,
2003). Acquired resistance to ADI-PEG20 has been an obstacle
in the long-term efficacy of this biomarker-driven therapy (Izzo
et al., 2004; Ott et al., 2013).
We hypothesized that understanding the metabolic response
to arginine starvation would allow for the identification of emergent vulnerabilities that, when targeted, convert a growth arrest
phenotype to a synthetic lethality. Therefore, we performed
capillary electrophoresis mass spectrometry (CE-MS) on metabolite extractions from cell lines acutely and chronically treated
with ADI-PEG20. Treatment caused dramatic alterations in
cellular metabolism, including glucose, glutamine, and serine
metabolism. We identify that arginine deprivation diverts glucose
into the serine biosynthetic pathway and renders ASS1-deficient
cells more sensitive to the inhibition of serine biosynthesis and
downstream folate-dependent enzymes, reinforcing the previously documented importance of serine biosynthesis in cancer
(Cantor and Sabatini, 2012; Locasale et al., 2011; Mattaini
et al., 2015). Finally, treatment also caused a switch from dependence on aerobic glycolysis (the Warburg effect) to glutamine
anaplerosis and OxPhos, thus identifying inhibition of glutamine
metabolism as a synthetic lethal target in arginine-starved cells.
Taken together, numerous metabolic alterations induced by
arginine starvation can be exploited therapeutically to induce
synthetic lethality in ASS1-deficient cancers.
RESULTS
Determining the Effects of Acute and Chronic Arginine
Deprivation on Metabolism
The immediate response to arginine starvation in ASS1-deficient
tumors is inhibition of cellular proliferation and induction of autophagy (Figures S1A and S1B; Bean et al., 2016; Delage et al.,
2012; Kim et al., 2009; Syed et al., 2013). During the period of
growth arrest, ASS1 is re-expressed in a c-Myc-dependent
manner, which allows cells to escape the effects of arginine
deprivation, overcome autophagy, and resume proliferation (Figure 1A; Figure S1A; Long et al., 2013; Tsai et al., 2012). To identify

Figure 1. Effects of Acute and Chronic Arginine Deprivation on Cell Growth and Metabolism
(A) Immunoblot measuring ASS1 and c-Myc expression in untreated WT, short-term ADI-PEG20-treated, and LTAT samples (representative of n = 3).
(B) Viable cell count normalized to plating density after short- and long-term ADI-PEG20 treatment (n = 3). Data are represented as mean ± SD.
(C) Metabolite levels in SKLMS1 WT NT, WT + ADI-PEG20, and LTAT cells (n = 2). Data are represented as mean ± SD.
G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; F1,6P, fructose-1,6,bisphosphate; 3-PG, 3-phosphoglycerate; 2-PG, 2-phosphoglycerate; a-KG,
a-ketoglutarate. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S1 and S2 and Table S1.
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synthetic lethal interactions with arginine starvation, we determined the metabolic alterations that occur when cells adapt
to acute and chronic arginine deprivation. To model the longterm effects of arginine deprivation and identify potential
synthetic lethal interactions, we continuously cultured three
cell lines that lack functional expression of ASS1 in the presence
of ADI-PEG20 for at least 3 months. This included two leiomyosarcoma cell lines (SKLMS1 and SKUT1) and a melanoma cell
line (SKMEL2) (Figure 1A). A melanoma line was included
to investigate whether the metabolic alterations identified were
a sarcoma-specific phenomenon or a general characteristic of
cellular metabolism in ASS1-deficient cancer cells. The longterm ADI-PEG20-treated (LTAT) cell lines are resistant to the
growth-inhibitory effects of arginine deprivation because of the
re-expression of ASS1 and reacquired de novo arginine biosynthesis capabilities (Figures 1A and 1B). Although ADI-PEG20induced arginine deprivation resulted in the inhibition of cellular
proliferation in wild-type (WT) cells, proliferation rates of LTAT
cell lines differed compared with their parental lines but did not
follow a consistent pattern (Figure 1B).
To investigate the metabolic changes resulting from both
short- and long-term arginine deprivation, we profiled the metabolome of the SKLMS1 wild-type cell line with and without
ADI-PEG20 treatment as well as the SKLMS1 LTAT cell line using
CE-MS. Profiling the major metabolites of purine and glutathione
metabolism, glycolysis, the TCA and urea cycle, and other pathways (Table S1) identified global metabolomic alterations upon
arginine deprivation and confirmed the depletion of intracellular
arginine and increase in citrulline expected with ADI-PEG20
treatment (Figure S2A). A heatmap of relative metabolite abundances displayed the three unique metabolic profiles of the
untreated WT, WT + ADI-PEG20, and SKLMS1 LTAT cells (Figure S2B). Because of negligible metabolic changes between
untreated SKLMS1 LTAT and SKLMS1 LTAT + ADI-PEG20 cells,
the untreated SKLMS1 LTAT line was dropped from further
studies, and all samples denoted ‘‘LTAT’’ were carried out
under continuous ADI-PEG20 treatment (Figure S2B). Principle
component analysis (PCA) confirms the three unique metabolite
profiles identified in the heatmap (Figure S2C). These results
demonstrate that both acute and chronic arginine deprivation
significantly alter cellular metabolism of the SKLMS1 cell line.
Treatment of SKLMS1 cells with ADI-PEG20 altered upper
and lower glycolysis, glutamine, and serine metabolism (Figure 1C). Additionally, the SKLMS1 LTAT line demonstrated an
accumulation of pyruvate and a depletion of glutamine (Figure 1C). We hypothesized that these metabolic alterations are
required for adaptation and eventual escape to the arginine
starvation-induced growth arrest and, thus, may be clinically
actionable targets.
Loss of PKM2 and Changes in Glucose Biology upon
Arginine Deprivation
Because PKM2 is an important regulatory enzyme in cancer
glycolysis, changes in total PKM2 levels and phosphorylation
status were determined in WT untreated, ADI-PEG20-treated,
and LTAT cell lines. A substantial decrease in PKM2 levels was
observed upon ADI-PEG20 treatment (Figure 2A). Levels of
phospho-PKM2 also decreased upon acute ADI-PEG20 treat-
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ment, demonstrating that altered PKM2 levels and phosphodriven changes in enzyme kinetics occur upon ADI-PEG20
treatment. The ratio of phospho-PKM2 to PKM2 with acute
ADI-PEG20 treatment demonstrates that both protein levels
and phosphorylation states are altered simultaneously (Figure 2A). The ratio in the LTAT cell lines follows no discernable
pattern (Figure 2A). The level of PKM1 remained constant (Figure 2A). Together, these data suggest that alterations in PKM2
kinetics may play a role in the changes in glycolysis seen upon
arginine starvation.
Next, we sought to determine whether the adaptation to arginine starvation altered cellular glucose dependence. Therefore,
WT and LTAT cell lines were cultured in low-glucose medium
(Figure 2B). When normalized to the proliferation rate of samples
grown in normal medium, there was no significant difference in
the proliferation rate of WT and LTAT samples in low-glucose
concentrations (Figure 2B). To further determine changes in
glucose biology upon arginine starvation, extracellular glucose
uptake was measured in cell lines treated with ADI-PEG20 as
well as LTAT cell lines and demonstrated lower glucose uptake
upon short- and long-term arginine deprivation (Figure 2C).
Taken together, this suggests that the underlying glucose
biology differs between WT and LTAT cell lines. Therefore, we
examined the ATP measurements from the CE-MS data and
found an acute decrease and long-term increase in ATP levels
in short-term ADI-PEG20-treated and LTAT cell lines, respectively (Figure S3A). Thus, we sought to determine whether
arginine deprivation altered the cellular dependence on mitochondrial ATP generation via OxPhos.
To test the OxPhos dependence of each cell line, samples
were treated with oligomycin, an inhibitor of complex V in the
electron transport chain. The LTAT lines were significantly
more sensitive to cell death by oligomycin, indicating an
increased reliance on mitochondrial OxPhos ATP generation
upon long-term ADI-PEG20 treatment (Figure 2D). Although
some of the wild-type cell lines experienced minor growth inhibition in the presence of oligomycin (data not shown), LTAT cell
lines invariably showed higher levels of cell death. The wildtype cell lines, therefore, appear to more closely follow the
phenotype described as the Warburg effect, whereby tumor
cells preferentially ferment glucose into lactate regardless of
the oxygen abundance available for glucose oxidation. LTAT
cell lines did not follow the classical definition of the Warburg
effect as closely as their respective WT cell lines, as illustrated
by the increased sensitivity to cell death by disruption of mitochondrial OxPhos (Figure 2D). Taken together, the data indicate
that the LTAT cell lines adapt to long-term ADI-PEG20 treatment by alterations in glucose metabolism and additionally
suggest that the response to arginine starvation in ASS1-deficient cell lines is an increased reliance upon OxPhos over aerobic glycolysis.
U13C Glucose Tracing Shows Upregulated GlucoseDependent Serine Biosynthesis
Next, we sought to identify the changes in glucose utilization
upon short- and long-term ADI-PEG20 treatment by utilizing
U13C glucose tracings and subsequent mass spectrometry.
The cellular abundance of 54 metabolites as well as all possible

Figure 2. Loss of PKM2 and Alterations in
Glycolysis after Arginine Deprivation
(A) Protein expression in untreated WT, WT + ADIPEG20, and LTAT cell lines. Densitometry was
performed on p-PKM2/PKM2 and PKM2/tubulin,
with relative expression normalized to untreated
levels shown (representative of n = 3),
(B) Normalized proliferation rates of cells grown in
various glucose concentrations after 36 hr (n = 3).
Data are represented as mean ± SD.
(C) Changes in glucose uptake upon short- and
long-term ADI-PEG20 treatment (n = 6). Data are
represented as mean ± SD.
(D) Oligomycin-induced cell death in WT and LTAT
cell lines as assayed by propidium iodide (PI)
fluorescence-activated cell sorting (FACS) (n = 3).
Data are represented as mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001. See also
Figure S3.

13

C isotopomers was determined after short- and long-term ADIPEG20 treatment. ADI-PEG20-treated cells exhibited a marked
decrease in 13C-labeled metabolites in the PPP and downstream
ATP/ADP/AMP, lactate, as well as TCA cycle intermediates
(6-phosphogluconolactone [6PG] and citrate, respectively, in
Figure 3A and ATP/ADP/AMP in Figure S3B). The decrease in
13
C-labeled lactate upon ADI-PEG20 treatment indicates a shift
away from aerobic glycolysis and is likely due to the concomitant
decreases observed in both lactate dehydrogenase A (LDHA)
levels and the activating phosphorylation of Tyr10 (Figure 2A;
Fan et al., 2011). The decreased carbon labeling of lactate and

PPP metabolites upon arginine deprivation is consistent with inhibition of the
Warburg effect.
Immunoblot analysis shows a significant decrease of pyruvate dehydrogenase subunit E1a upon arginine deprivation as well as a simultaneous increase
in the inactivating phosphorylation of
Ser300 on E1a (Figure 2A; Rardin et al.,
2009). These alterations would decrease
the contribution of glucose-derived carbons to acetyl-CoA and TCA cycle intermediates and increase the need for
TCA cycle anaplerosis via other carbon
sources.
Upon ADI-PEG20 treatment, glucosederived carbons are shunted into the
serine biosynthesis pathway, as demonstrated by U13C-glucose tracing (Figure 3A). Immunoblotting for phosphoglycerate dehydrogenase (PHGDH), the
first and rate-limiting enzyme in the
biosynthesis of serine, showed a significant upregulation upon acute arginine
deprivation, with either stable levels or
further increases in LTAT cell lines (Figure 2A). Direct inhibition of PHGDH with
the small-molecule inhibitor CBR-5884 was found to cause
significantly greater levels of cell death when paired with ADIPEG20 treatment (Figure 3B; Mullarky et al., 2016). Although
13
C labeling of serine from glucose in LTAT cell lines returned
to levels similar to wild-type cell lines, LTAT lines demonstrated
increased sensitivity to PHGHD inhibition with CBR-5884
compared with the WT lines as well as increased 13C labeling
in glycine, indicating continued dependence on the serine
biosynthesis pathway (Figure 3C).
Serine is converted into glycine by removal of a single carbon
in a folate-dependent reaction, where both glycine and the single
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Figure 3. Glucose and Serine Metabolism after Arginine Deprivation
(A) Average relative and normalized isotopomer abundance from U13C glucose in SKLMS1 WT NT, WT + ADI-PEG20, and SKLMS1 LTAT cell lines. Red arrows
indicate increased 13C flux upon short-term treatment (n = 3).
(B) Cell death induction in WT cell lines after treatment with ADI-PEG20 and/or CBR-5884 as measured by PI FACS (n = 3). Data are represented as mean ± SD.
(C and D) PI FACS measurement of cell death in WT and LTAT cell lines after treatment with CBR-5884 (n = 3) (C) or treatment with MTX (n = 3) (D). Data are
represented as mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.
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carbon transferred to the folate cofactor are required for the
biosynthesis of purines and pyrimidines (Lane and Fan, 2015;
Locasale, 2013). We therefore assayed cellular susceptibility to
methotrexate (MTX), an anti-folate analog that inhibits dihydrofolate reductase and stops folate cycle-dependent single-carbon
metabolism. Upon methotrexate treatment, LTAT cell lines
showed a significantly higher level of cell death than WT cell lines
(Figure 3D). The significant increase in cell death with methotrexate and CBR-5884 in LTAT lines is consistent with the upregulation in serine and glycine biosynthesis seen in the 13C tracing
data by the increased label seen in glycine, indicating the
continued upregulation of glucose flux through the serine
biosynthesis pathway upon short- and long-term ADI-PEG20
treatment.
Changes in Glutamine Dependence and Utilization after
Arginine Deprivation
To determine cellular reliance on glutamine, WT and LTAT cell
lines were cultured in glutamine-free medium. LTAT lines were
significantly more susceptible to glutamine withdrawal than their
WT counterparts (Figure 4A). From the CE-MS data, cellular
abundance of glutamine decreases significantly in a time-dependent fashion upon ADI-PEG20 treatment; longer treatment is
associated with more profound reductions in glutamine levels
(Figure 4B). This loss reflects increased usage of glutamine as
opposed to decreased biosynthesis because the cell lines
were cultured in excess glutamine. A significant increase in
extracellular uptake of radiolabeled glutamine ([3H]-Gln) after
short-term ADI-PEG20 treatment and further increases in uptake
upon long-term treatment demonstrate the increased utilization
of glutamine upon arginine deprivation (Figure 4C). Glutamine
is shunted into the TCA cycle upon arginine deprivation, with
each of the cell lines showing either increased glutaminase
(GLS) and/or glutamate dehydrogenase (GDH) protein levels
upon ADI-PEG20 treatment (Figure 4D). Additionally, short
hairpin RNA (shRNA)-mediated GLS knockdown decreases
cell viability under conditions of glucose deprivation, demonstrating the dependence on the metabolic shift to glutamine utilization in the absence of glucose (Figure S4). Taken together,
these data suggest that arginine deprivation increases the rate
of glutamine anaplerosis and oxidation through the TCA cycle.
The decrease in 13C glucose-derived TCA cycle intermediates
upon ADI-PEG20 treatment (Figure 3A) suggests an increased
flux of other carbon sources into the TCA cycle, with data suggesting an ADI-PEG20-induced upregulation of glutamine anaplerosis. To demonstrate an increased rate of glutamine flux
into the TCA cycle and alterations in the fate of glutamine upon
short- and long-term ADI-PEG20 treatment, SKLMS1 lines
were cultured with U13C glutamine and subjected to metabolite

extraction and CE-MS. Tracing the five 13C-labeled carbons
from glutamine demonstrates entrance into the TCA cycle, subsequent oxidative decarboxylation, oxidation, and hydration to
form malate, with further oxidation to oxaloacetate and cataplerosis for the biosynthesis of aspartate and asparagine (Figure 4E).
The increase in the four 13C labels seen in malate upon ADIPEG20 treatment informs this directionality. Additionally, dramatic upregulation in asparagine synthetase (ASNS) occurred
concurrently with the significant increase in asparagine labeling
(Figure 4D). The total relative amount of 13C-labeled citrate
decreased, with small increases in five 13C labeling in citrate suggesting a slight increase in the rate of reductive decarboxylation.
Finally, no significant increase in 13C accumulation in cytidine
triphosphate (CTP) or uridine triphosphate (UTP) was seen (Figure S5), and a small component of glutamine-derived 13C was
found to be utilized in glutathione biosynthesis (Figure 4E). Taken
together, we find that glutamine anaplerosis is upregulated upon
ADI-PEG20 treatment, with the major benefactor being amino
acids, specifically aspartate and asparagine.
Inhibition of the Warburg Effect after Arginine
Deprivation
Because arginine deprivation caused an increase in glutamine
utilization (Figure 4), an increase in susceptibility to cell death
by oligomycin treatment (Figure 2D), and a decrease in glucose
fermentation into lactic acid (Figure 3A), we hypothesized that
the changes in the metabolic network upon ADI-PEG20 treatment resulted in an inhibition of the Warburg effect. To test this
hypothesis, we used the Seahorse XF96 to profile the metabolic
phenotypes of cells under normal conditions and in the context
of arginine starvation. When measuring the extracellular acidification rate (ECAR), an indicator of lactic acid fermentation, we
observed a significant increase in ECAR of untreated cells
upon addition of glucose to the medium. However, when cells
were pretreated with ADI-PEG20, the increase in extracellular
acidification upon addition of glucose was significantly blunted
(Figure 5A). This suggests that untreated cells preferentially
ferment glucose into lactic acid at a higher rate than cells
treated with ADI-PEG20, which have a decreased rate of glucose
fermentation.
Mitochondrial respiration was profiled by measurements of
the oxygen consumption rate (OCR) to determine changes in
the level of OxPhos-dependent ATP generation upon arginine
deprivation. The spare respiratory capacity, or the ability of the
mitochondria to generate additional ATP via the electron transport chain when under conditions of energy stress, was significantly decreased in cells treated with ADI-PEG20 (Figure 5B).
This indicates that the mitochondria in these cells are less
capable of upregulating OxPhos ATP generation upon increased

Figure 4. Glutamine Metabolism after Arginine Deprivation
(A) Normalized viable cell counts of WT and LTAT cell lines grown in glutamine-free medium after 24, 48, or 72 hr (n = 3). Data are represented as mean ± SD.
(B) Metabolite levels in SKLMS1 WT NT, WT + ADI-PEG20, and LTAT cell lines (n = 2). Data are represented as mean ± SD.
(C) Normalized measurements of [3H]-Gln uptake after short- and long-term ADI-PEG20 treatment (n = 12). Data are represented as mean ± SEM.
(D) Immunoblot analysis of enzymes involved in glutamine metabolism and asparagine biosynthesis upon treatment with ADI-PEG20 (representative of n = 3).
(E) Average relative and normalized isotopomer abundance from stable isotope tracing of U13C glutamine in SKLMS1 WT NT, WT + ADI-PEG20, and SKLMS1
LTAT cells (n = 3).
*p < 0.05, **,p < 0.01, ***p < 0.001. See also Figures S4 and S5.
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Figure 5. Inhibition of the Warburg Effect after Arginine Deprivation
(A and B) Normalized measurements of ECAR (A) and OCR (B) upon ADI-PEG20 treatment (WT, n = 11; ADI, n = 12).
(C) Percent of ATP generated from glycolysis in WT and LTAT cell lines (WT, n = 11; LTAT, n = 12).
(D) Plot of ECAR versus OCR measurements upon short- and long-term ADI-PEG20 treatment (WT, n = 11; ADI, n = 12; LTAT, n = 12).
All data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***,p < 0.001. See also Figure S6.
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energy demand than the mitochondria of untreated cells. The
increased sensitivity of LTAT cell lines to cell death by oligomycin
further suggests an increased reliance on OxPhos under conditions of arginine deprivation (Figure 2D). Additionally, the percentage of total cellular ATP generated from glycolysis is
significantly decreased in LTAT cell lines compared with WT
cell lines (Figure 5C). The decrease in lactic acid fermentation
and increased rate of OxPhos indicate that arginine deprivation
can inhibit the Warburg effect. As shown by the energetic
profiling (Figure 5D), glycolytic WT cell lines decrease the
ECAR and increase the OCR upon short- and long-term ADIPEG20 treatment as they downregulate the Warburg effect and
upregulate OxPhos in response to arginine starvation.
Previous studies in breast cancer have shown a decrease in
mitochondrial OxPhos upon treatment with ADI-PEG20 because
of decreased Cox4 expression, in contrast to the cellular
response to arginine deprivation we identified (Qiu et al., 2014).
When our samples were examined for Cox4 expression using
the same antibody, no consistent pattern emerged, with
SKLMS1 demonstrating increased Cox4 expression (Figure S6).
This may reflect a difference in the biology of breast cancer
compared with melanoma and sarcoma or a difference in the
breast cancer cell line response to ADI-PEG20 treatment.

xenografts were utilized to recapitulate the synthetic lethality
in vivo. Xenografts with shGLS constructs demonstrated
approximately a 12-day delay in growth to 100 mm3 compared
with the shGFP control tumors; when established, all tumors
grew at approximately the same rate (Figure 6E). When experimental tumors reached approximately 100 mm3, ADI-PEG20
was injected intramuscularly once every 3 days. Although ADIPEG20 treatment caused the shGFP control tumors to remain
static for a short period of time before gaining resistance to the
drug and resuming growth, the shGLS tumors shrank significantly upon treatment with ADI-PEG20 (Figure 6E). These results
indicate that treatment with ADI-PEG20 and simultaneous GLS
inhibition decreases the tumor burden in vivo. Analysis of xenografts on day 30 showed ASS1 re-expression or selection for
a subpopulation of cells with less effective GLS knockdown,
likely mechanisms of acquired resistance to ADI-PEG20 growth
inhibition (Figure 6F), further supporting in vivo synthetic lethality.
Finally, LTAT shGFP and shGLS tumors treated with ADI-PEG20
grew at the same rate as the untreated WT shGFP tumors; selection for LTAT shGLS cells likely induced further reprogramming
of cellular metabolism to compensate for the increased reliance
on glutamine seen in the LTAT lines (Figure S7).
DISCUSSION

Targeting Upregulation of Glutamine Metabolism
Causes Synthetic Lethality
The increased reliance on glutamine anaplerosis and OxPhos
upon arginine deprivation identifies a potential synergy in
arginine deprivation and inhibition of glutamine metabolism.
To test the potential for a synthetic lethal interaction between
ADI-PEG20 treatment and inhibition of glutamine metabolism,
cell lines were treated with either ADI-PEG20, a GLS inhibitor (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
[BPTES]), or the two drugs in combination. The combination of
ADI-PEG20 and BPTES resulted in a significantly greater reduction in viable cell number than either drug individually (Figure 6A)
and a greater increase in cell death upon simultaneous treatment
than either drug individually (Figure 6B). To ensure that these
results were not a consequence of an off-target effect, the synthetic lethality was tested in cell lines after GLS shRNA knockdown (Figure 6C). In the GLS knockdown cells, treatment with
ADI-PEG20 reduced the viable cell number to the same degree
as treatment with ADI-PEG20 and BPTES in combination, as
opposed to the control cell lines, where only the combination
of treatments demonstrated a synergetic interaction, indicating
minimal off-target effects (Figure 6C). We then tested a broad
range of ASS1-deficient cell lines identified from the NCI-60
cell line (including breast, colon, lung, glioblastoma, and head
and neck cancer cell lines), a patient-derived xenograft breast
cancer cell line, and an osteosarcoma cell line with ADI-PEG20
and BPTES and found the combination to similarly result in a
greater reduction in viable cell count than either drug individually
(Figure 6D).
Unfortunately, in vivo experiments using BPTES in mice were
prevented by crystallization of the compound upon injection.
Therefore, as an alternative, shRNA targeting the coding
sequence for glutaminase (shGLS) and shRNA targeting the
coding sequence for green fluorescent protein (shGFP) SKMEL2
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We demonstrate that the removal of arginine from ASS1-deficient, arginine auxotrophic cancers rapidly alters metabolism,
downregulates the Warburg effect, and upregulates glutamine
anaplerosis (Figure 7). Interestingly, targeting a defect in the
urea cycle can lead to the upregulation of OxPhos, glutamine
metabolism, and serine biosynthesis. This shift renders cells
vulnerable to synthetic lethal metabolic strategies in which
ADI-PEG20 induces arginine starvation, whereas glutaminase
inhibitors suppress the compensatory reliance on glutamine
and PHGDH inhibitors prohibit the upregulation of serine biosynthesis. Although neither GLS inhibition nor arginine deprivation
alone is sufficient to induce high levels of cell death because of
the rapid metabolic reprogramming that occurs upon singleagent exposure, together they are therapeutically effective at
killing tumor cells and suppressing tumor growth. ADI-PEG20
also diverts glucose into serine biosynthesis and subsequent
downstream single-carbon folate metabolism, sensitizing cells
to anti-folate metabolites such as methotrexate.
Many defects in metabolism have been identified in cancer,
including ASS1 deficiency, isocitrate dehydrogenase (IDH) mutations, overexpression of PKM2, succinate dehydrogenase
and fumarate hydratase deficiencies, and mutations in various
mitochondrial complex proteins (Rohle et al., 2013). With the
exception of IDH mutations in leukemia being sensitive to AG221 (an inhibitor of IDH) monotherapy, single-agent metabolic
targeting usually leads to rapid tumor metabolic re-networking
and therapeutic resistance (Allen et al., 2014; Gaude and Frezza,
2014; Sasaki et al., 2012). Here we demonstrate that, by
measuring the global metabolic changes in response to arginine
deprivation, we can not only identify adaptive pathways but also
develop therapies to target them. Importantly, this is the first
reported dual metabolic synthetic lethal therapeutic strategy
for cancer that relies solely on targeting metabolic pathways as

Figure 6. ADI-PEG20 Treatment and Glutamine Metabolism Inhibition Induce Synthetic Lethality
(A and B) Normalized viable cell counts (n = 3) (A) and PI FACS measurement of cell death (B) after treatment with ADI-PEG20 and/or BPTES (n = 3). Data are
represented as mean ± SD.
(C) Normalized viable cell counts after ADI-PEG20 and/or BPTES treatment in shGFP and shGLS cell lines (n = 3). Data are represented as mean ± SD.
(D) Normalized viable cell count after treatment with ADI-PEG20 and/or BPTES in a variety of cancer types. Statistics represent significance between samples
treated with ADI-PEG20 and BPTES and samples from other treatment conditions (n = 3). Data are represented as mean ± SD.
(E) Tumor volume of SKMEL2 WT shGFP and shGLS xenografts left untreated and treated with ADI-PEG20. Data are represented as mean ± SEM. Statistics
represent significance between shGFP and shGLS tumors treated with ADI-PEG20 (n = 5).
(F) Immunoblot analysis of SKMEL2 WT shGFP and shGLS tumors harvested following treatment with ADI-PEG20 for 30 days.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S7.
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lite extraction method for adherent cells. Metabolite concentrations were
normalized to viable cell counts.
For U13C tracings, SKLMS1 lines were plated with or without 1 mg/mL ADIPEG20 for 48 hr, and then U13C-labeled medium was added. U13C glucose
and U13C glutamine (Cambridge Isotope Laboratories) medium contained
glucose at 4.5 g/L and glutamine at 2 mM and was incubated with or without
1 mg/mL ADI-PEG20 for 48 hr. After an additional 24-hr incubation period,
methanol metabolite extraction was performed according to the HMT metabolite extraction for adherent cells protocol. Data were corrected for the natural
abundance of the stable isotope.

Figure 7. Model of Arginine Deprivation-Induced
Changes in ASS1-Deficient Cancers

Metabolic

Model of metabolic changes upon ADI-PEG20-induced arginine deprivation
causing the shift of glucose from aerobic glycolysis to glucose-dependent
serine biosynthesis and the simultaneous upregulation of glutamine anaplerosis and aspartate and asparagine biosynthesis. THF, tetrahydrofolate;
meTHF, 5,10-methylenetetrahydrofolate.

opposed to layering a metabolic strategy on top of the current
standard of care, such as chemotherapy, in an attempt to
improve efficiency.
Another key observation is the realization that the Warburg
effect can be exploited for therapeutic benefit. ADI-PEG20
treatment of glycolytic, ASS1-deficient cell lines resulted in inhibition of the Warburg effect. These changes were accompanied by a simultaneous redirection of glucose through the
serine biosynthetic pathway and compensatory engagement
of a survival program utilizing glutamine anaplerosis to harness
the TCA cycle for energy and biomass generation. By altering
how cancer cells utilize glucose, we can disrupt the ability of
tumor cells to build the biomass necessary to sustain rapid
cellular division.
Finally, using a global metabolomic approach to study the
acute and long-term effects of arginine starvation in ASS1deficient tumors, we develop a paradigm in which changes
in metabolic pathways can be used to develop multidrug,
biomarker-driven cancer therapies that exploit the unique metabolism of cancers. The ability to acutely alter the metabolome
and thereby induce shifts in nucleotide synthesis, amino acid
composition, and lipid metabolism has the potential to uncover
other metabolic vulnerabilities specific to cancer cells. It is
our hope that we can utilize this type of biomarker-directed
approach to selectively starve and then kill cancer cells with
minimal effect on normal tissues.

Extracellular Flux Analysis
Samples were plated in a 10-cm dish with or without ADI-PEG20. After 48 hr,
cells were collected, and 20,000 cells were plated per well in a 96-well
Seahorse plate with normal or ADI-PEG20 pretreated medium. Assays were
performed 18–24 hr after plating with a XF96 analyzer. Oligomycin, rotenone,
and antimycin A were used at 10 mM, and carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) was used at 5 mM in Mito tests. Glucose was
used at 10 mM, oligomycin at 5 mM, and 2-Deoxy-D-glucose (2-DG) at
100 mM for glycolysis tests. OCR measurements from mitochondrial stress
tests are normalized to basal respiration rate, and ECAR measurements
from glycolysis stress tests are normalized non-glycolytic ECARs. Percent
glycolytic ATP was calculated with values of glycolytic ATP obtained from
the glucose-induced proton production rate and OxPhos ATP obtained
from oligomycin decrease in OCR. All materials were obtained from Agilent
Technologies.
Statistics
Comparisons were performed with a Student’s t test with p values denoted as
*p < 0.05, **p < 0.01, and ***p < 0.001 (NS, not significant).
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